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ABSTRACT 
Objective: To develop a rapid, accurate, linear, sensitive and stability indicating RP-HPLC method for the determination of nilotinib in bulk and 
pharmaceutical dosage forms in the presence of its four related substances.  
Methods: The RP-HPLC method was developed for the chromatographic separation of nilotinib and its impurities by using waters Xterra RP-18 
(150*4.6 mm, 3.5 µm) column with a mobile phase combination of 10 mM ammonium formate with pH-3.5 and acetonitrile in gradient mode. An 
injection volume of 20 µl. Flow rate was 1.0 ml/min and detection was carried a wavelength of 250 nm. The method was validated as per ICH 
guidelines.  
Results: The retention time for nilotinib and its four impurities were found to be 4.37, 7.40, 8.96, 10.21 and 10.87 min respectively. The linear regression 
analysis data for the calibration plots showed the good linear relationship in the concentration range of 0.04-3.0 ppm for the nilotinib impurities. The % 
recovery of nilotinib impurities was found to be 96.8-99.4% in the linearity range. The detection limit (LOD) values were about 0.014, 0.016, 0.005 and 0.03 
ppm respectively and the quantification limit (LOQ) values were 0.042, 0.048, 0.014 and 0.09 ppm respectively. The % degradation at various stress 
conditions like acid, alkaline, oxidative, thermal and photolytic stress was found to be 8.92, 18.35,5.63, 0.88 and 3.89 respectively. 
Conclusion: The RP-HPLC method compatible with LC-MS was developed for the analysis of nilotinib and its four impurities. It was validated as per 
the ICH guidelines and found to be linear, robust, precise, accurate, sensitive, stability indicating and can be used for routine as well as stability 
analysis of capsule dosage forms as well as for drug substance. 
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Nilotinib is a synthetic amino pyrimidine, a second generation 
tyrosine kinase inhibitor used for the treatment of imatinib-resistant 
chronic myelogenous leukemia in the form of nilotinib 
hydrochloride monohydrate salt. Nilotinib has around 20 times 
higher affinity over imatinib and has an in vitro activity against many 
imatinib-resistant mutants [1, 2]. It is used to treat people who have 
tested positive for Philadelphia chromosome, a common genetic 
abnormality found in people having chronic myeloid leukemia 
(CML). CML is also known as chronic granulocytic leukemia (CGL). It 
is a cancer of white blood cells that occurs due to the increased and 
unregulated growth of myeloid cells in bone marrow and their 
accumulation in the blood. CML is a clonal bone marrow stem cell 
disorder in which a proliferation of mature granulocytes and their 
precursors is found. CML is now largely treated and targeted with 
drugs like tyrosine kinase inhibitors like imatinib, nilotinib, and 
dasatinib that led to improved long-term survival rates since the 
introduction of first such agent.  
The presence of impurities can have a significant impact on the 
product quality, safety and efficacy, hence the percentage level of 
impurities need to control in the drug substance as well as a drug 
product. An extensive literature survey reveals that there were few 
analytical methods available for the determination of nilotinib in 
plasma, biological fluids, bulk and in pharmaceutical dosage forms 
by liquid chromatography and liquid chromatography mass 
spectrometry (LC-MS) techniques [3-12]. The objective of the 
current work is to develop a simple, precise, accurate, robust and 
stability indicating LC-MS compatible HPLC method for the 
determination of nilotinib hydrochloride and its related impurities 
in bulk and pharmaceutical dosage forms, followed by method 
validation as per current International conference on harmonization 
(ICH) guidelines.  
MATERIALS AND METHODS 
Chemicals and reagents 
Nilotinib hydrochloride drug substance was gifted by the synthetic 
division of Hetero laboratories Ltd, Hyderabad, India. Acetonitrile, 
methanol and ethanol of HPLC grade (Rankem chemicals, India). 
Ammonium formate, sodium hydroxide, hydrochloric acid and 
hydrogen peroxide (Merck chemicals, Darmstadt, Germany). HPLC 
grade water was obtained from milli-Q water purification system 
(Millipore, Milford, USA).  
Instrument 
The HPLC system used for the chromatographic method 
development, forced degradation and validation was Agilent-1260 
quaternary pump separation module with a PDA detector. HPLC 
system consisted of quaternary pump G1311C and photodiode array 
detector G4212B. The signal output was monitored and processed 
using EZ chrome Elite software on a Lenovo computer. 
Chromatographic separation was achieved on waters Xterra RP-18 
150*4.6 mm, with a particle size of 3.5 µm was used. pH of the 
mobile phase was adjusted on a microprocessor waterproof pH 
tester (pH tester 20, Eutech instruments, Oakton, USA). Thermal 
degradation study was carried out in a dry, hot air oven (Ultra 
Biotech, Bangalore, India) and photolytic degradation is carried out 
on photostability chamber. (Atlas suntester CPS+, Illinois, USA). 
Physical properties 
The chemical name of nilotinib hydrochloride monohydrate is 4-
methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(triflouromethyl)-
phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl) amino] benzamide 
hydrochloride monohydrate fig. 1 with molecular formula 
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C28H22F3N7O. HCl. H2O. It is white to slightly yellowish crystalline 
powder with melting range of 288-290 °C. The molecular mass of 
nilotinib is 529.52 while 583.99 for nilotinib hydrochloride 
monohydrate. 
 
Fig. 1: Structure of nilotinib hydrochloride monohydrate 
 
pKa and solubility  
Nilotinib is a typical Biopharmaceutical classification system (BCS) a 
class-IV compound having poor solubility and poor permeability. 
Nilotinib solubility decreases with increase in aqueous pH indicating 
pH dependent solubility. Nilotinib is practically insoluble in buffer 
solutions with pH-4.5 and higher pH values. It is slightly soluble at 
pH-1.0. The solubility was determined at 37 °C by using UV-visible 
spectrophotometer at 250 nm wavelength. UV spectrum of nilotinib 
in pH-2.0 buffer was plotted below in fig. 2. It clearly indicates 
nilotinib was having a maximum absorbance in the range of 250-270 
nm. The solubility of nilotinib in water is around 0.024 mg/liter at 
25 °C. Nilotinib is sparingly soluble in ethanol and methanol. pKa1 of 
nilotinib is 2.1 and pKa2 is 5.4. 
Methods 
Chromatographic conditions 
The aim of the study was to develop a single and simple LC-MS 
compatible stability indicating HPLC method for the separation of 
related substances with possible lowering of retention time at a 
column temperature of 40 °C. Separation was achieved using 
gradient elution mode with 10 mM ammonium formate with pH-3.5 
and acetonitrile as mobile phase with a run time of 14 min. The 
retention time of nilotinib was found to be around 8.0 min. Filtered 
the mobile phase through 0.22 µm nylon membrane filter and 
degassed. Injection volume was 20 µl with a mobile phase flow rate 
of 1.0 ml/min. The detection wavelength was 250 nm. Buffer: 
acetonitrile in the ratio 50:50 V/V was used as diluent. 
  
 
Fig. 2: UV Spectrum of nilotinib hydrochloride 
 
LC-MS conditions 
The LC-MS system used for the identification of related substances 
of nilotinib formed during the forced degradation study was agilent 
system equipped with mass lynx software. Waters xterra RP-18, 
150*4.6 mm, 3.5 µm HPLC column was used as stationary phase 
with a mobile phase containing a gradient of 10 mM ammonium 
formate (0.63 g of ammonium formate) in 1000 ml of milli q water 
and acetonitrile in the ratio 90:10 % V/V as solvent A and pH-3.5 
buffer: acetonitrile in the ratio 10:90 % V/V as solvent B. The flow 
rate was 1.0 ml/min with a gradient programme of 0.0/10, 2.0/10, 
8.0/80, 10.0/80, 12.0/10 and 14.0/10 (time in min/% B). The 
injection volume was 10 µl. The analysis was performed on positive 
and negative modes of electron spray ionization modes with a mass 
scan range of 50-1000 m/z capillary voltage is 3700V, end plate 
offset-500V, charging voltage 2000V, the corona current as 10 nA. 
Nebulizer pressure as 0.3 bar. Source temperature and desolvation 
temperatures were 180 and 360 °C respectively. Cone gas flow was 
4.0 L/min and desolvation gas flow was 10.0 L/min.  
Buffer preparation 
Dissolved accurately 0.63 g of ammonium formate in 1000 ml of 
milli-q water and mixed well to prepare 0.010 M solution of the 
solution, further adjusted the pH to 3.5 with formic acid. The buffer 
solution was filtered through 0.22 µm membrane filter. 
Standard preparation 
A working standard solution stock of nilotinib hydrochloride was 
prepared by dissolving 50 mg of the standard into 100 ml 
volumetric flask, to this added 30 ml of diluent and sonicated for 10 
min. Allowed the solution to attain room temperature and diluted to 
the volume with diluent to have a solution with a concentration of 
500 ppm. 
Diluted standard preparation 
Diluted 2 ml of the standard solution to 50 ml with diluent and 
mixed well. Further diluted 2 ml of the resulting solution to 100 ml 
with diluent and mixed well to a concentration of 0.4 ppm. 
Sample preparation 
Weighed 20 capsules and determined the average weight of the 
capsule. The capsules were emptied carefully and collected the 
content of 20 capsules. Transferred sample equivalent to 100 mg of 
nilotinib into 50 ml volumetric flask added 30 ml of diluent and 
sonicated for 10 min with intermediate shaking in sonicator at a 
temperature below 25 °C. The solution was cooled to room 
temperature and diluted with diluent to a concentration of 1000 
ppm. The solution was filtered through 0.22 µm nylon membrane 
filter. 
Validation of the developed method 
The optimized analytical method was validated according to the 
International conference on harmonization (ICH) guidelines for 
analytical procedures Q2 (R1) [13, 14]. 
System suitability 
According to the United States pharmacopeia (USP), system 
suitability test should be performed prior to analysis. System 
suitability test was performed to ensure the system performance 
before initiating the experiment, by monitoring the parameters like 
% RSD, theoretical plates, resolution and asymmetry. 
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Specificity 
Specificity is the ability of the method to measure the analyte 
response in the presence of its potential impurities [15]. 
Linearity 
The linearity of the detector response was established for all the 
known impurities with concentration ranging from LOQ to 150 % of 
the specification level (0.10 %) with respect to test concentration. 
The samples were analyzed as per the described test method. A 
linearity graph was plotted between the area of impurity (Y-axis) 
versus actual concentration in ppm (X-axis) and determined the 
coefficient of correlation and Y-intercept at 100 % response.  
Precision 
The precision of the analytical method is the closeness agreement 
for a series of measurement from multiple samplings as mentioned 
in ICH Q2 (R1). As per the guidelines, method precision and 
intermediate precision were analyzed on the homogeneous sample 
and the % RSD of individual impurity for precision and intermediate 
precision was calculated and reported. 
Accuracy 
The accuracy of the analytical method is the closeness of agreement 
between the true value and experimental value. The accuracy of the 
four impurities was performed at levels ranging from LOQ to 150 % 
of the specification level of the impurity with respect to test 
concentration level. The % recovery was calculated by comparing 
the impurity level at each level of the spiked sample with as such 
sample. 
LOD and LOQ 
The detection limit (LOD) and quantification limit (LOQ) for all the 
four impurities were established by means of linearity method. The 
impurity solutions from concentration ranging from 0.01 % to 0.10 
% with 5 different levels in duplicate were prepared and injected. 
Based on the impurity response and STEYX value, the least 
concentration of each impurity up to which it can be identified and 
quantified was calculated. 
Robustness 
The robustness of the method was evaluated to establish the 
capability of the method by changing the experimental conditions 
and studying its impact on the system suitability. Robustness was 
performed by changing the method parameters like mobile phase 
flow rate and column temperature. 
RESULTS 
Method development and optimization 
As there was no stability indicating HPLC method available for the 
separation of nilotinib from its related substances, the objective of 
the method was to separate the analyte peak from the potential 
impurities arise during the forced degradation study. There was no 
LC-MS compatible HPLC method available for the identification of 
degradants during stability period and storage conditions. For the 
optimization of the HPLC method, forced degradation sample was 
taken as reference. There was spectral co-elution in the case of these 
impurities on different stationary phases like C8, C18 and phenyl 
with different buffer ratios and organic modifiers like methanol and 
acetonitrile. Nilotinib is having better solubility in the range of pH-
2.0 to 4.0, hence buffers with varying concentrations were chosen in 
this pH range. Initial trials were taken on pH-2.4 phosphate buffer 
with acetonitrile as mobile phase and test concentration of 1000 
ppm in mobile phase was injected in which there was no clear 
separation between the impurities and nilotinib. Further trials were 
taken by varying the pH value of the mobile phase buffer from 2.0 to 
3.5. i.e., ammonium formate buffer was selected as a mobile phase 
buffer as it had the maximum buffering capacity at its pKa (pKa of 
ammonium formate is 3.5). Forced degradation sample was injected 
and was found that all the four impurities were spectrally pure with 
longer run time and broader peak shapes. In order to shorten the 
run time gradient separation mode was optimized with satisfactory 
separation. Optimal separation was achieved on waters xterra RP-18 
150*4.6 mm, 3.5 µm HPLC column maintained at 40 °C. Gradient 
elution was performed using the mixture of 10 mM ammonium 
formate buffer pH-3.5 (pH was adjusted with formic acid) and 
acetonitrile as mobile phase at a flow rate of 1.0 ml/min and UV 
detection at 250 nm. Fig. 3 shows separation of all the four 
impurities from nilotinib hydrochloride in the proposed method.
 
 




System suitability was verified by replicate analysis of 6 injections of 
nilotinib diluted standard solution and the chromatogram obtained. 
The system suitability parameters such as asymmetry, theoretical 
plate count and reproducibility (% RSD) of analyte retention time 
(Rt) and area of the six replicates were calculated from the 
chromatogram. System suitability parameters were mentioned in 
table 1. 
Specificity 
The specificity of the method was evaluated for nilotinib 
hydrochloride in the presence of its blank, placebo, known 
impurities and other degradation products. Forced degradation 
studies were performed on nilotinib drug substance and drug 
product to verify the stability indicating property and specificity of 
the proposed method. Stress studies were performed under 
conditions of acidic, alkaline, hydrolytic, peroxide, thermal and 
photolytic as mentioned in ICH Q1A (R2). The forced degradation 
study was initiated based on the approach suggested by Blessy M 
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and Ruchi DP [16]. Four samples (Blank, drug substance, drug 
product and placebo) were generated for every stress condition and 
were compared against the unstress (as such) solutions for the net 
amount of degradation. Acidic degradation of nilotinib was 
conducted at 60 °C in 0.1 N HCl, alkaline degradation at 0.1 N NaOH 
at 60 °C for 4 h, water at 80 °C, peroxide degradation with 3 % H2O2 
at room temperature for 1 hr at a drug concentration of 1000 ppm 
until sufficient degradation of the drug (~ 20 % of the initial 
amount) was achieved. Thermal stress was performed at 105 °C for 
drug substance, drug product, and placebo till 48 h. Photolytic stress 
was performed by exposing the sample to ultraviolet radiation of an 
overall energy of 200-watt hours/m2andvisible radiation of 1.2 
million lux hours [17]. The peak purity of the stressed sample was 
evaluated by EZ chrome software such that the peak purity should 
be greater than 0.99, demonstrating the homogeneity of the peak. 
The forced degradation samples were analyzed on LC-MS to obtain 
the molecular masses of the potential degradant and the structure 
was further confirmed by analyzing the isolated sample by NMR. The 
impurities structures in fig.4, along with the mass numbers were 
tabulated below along with relative retention time (RRT) in table 2. 
 
Table 1: System suitability report 
Injection Rt* (Min) Area Asymmetry Theoretical plates 
1 7.41 421531 1.12 7854 
2 7.41 420145 1.15 7844 
3 7.40 421935 1.18 7801 
4 7.40 420889 1.11 7832 
5 7.42 421008 1.13 7862 
6 7.41 420045 1.11 7870 
Average 7.41 420925.5 1.13 7844 
SD 0.01 745.43 0.03 24.87 
% RSD 0.10 0.18 2.41 0.32 
*Rt-Retention time 
 
Table 2: Impurities name, RRT and m/z value 
S. No. Name Rt *(min) RRT# m/z value 
1 Nilotinib(imp-I)  4.37  0.58 530.19 
2 Nilotinib HCl  7.40  1.00 564.16 
3 Acid impurity (imp-II)  8.96  1.21 307.13 
4 Amide impurity (imp-III)  10.21  1.39 305.13 
5 N-Oxide (imp-IV)  10.87  1.47 544.22 




Fig. 4: Structures of nilotinib hydrochloride and its impurities 
 
Precision 
Method precision and intermediate precision analysis were 
performed on the homogeneous sample. The % RSD of individual 
impurity for precision and intermediate precision should be not 
more than 15.0 and was observed for the 12 samples around 4.0 % 
for each individual impurity. 
Method precision 
Six different test samples were prepared as per the test method by 
spiking nilotinib hydrochloride impurity-I, impurity-II, impurity-III 
and impurity-IV at 0.10 % level with respect to test concentration. 
The % impurity level for the six samples was calculated by the 
diluted standard method. The % impurity in the unspiked sample 
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was subtracted from spiked sample and reported the % impurity for 
each sample. 
Intermediate precision 
Six different samples were prepared by spiking the impurity at 0.10 
% level with respect to test concentration and analyzed as per the 
method on a different day, different HPLC system and different HPLC 
column of the same make or equivalent. The % impurity levels for 
the six samples were calculated by the diluted standard method and 
reported the % of each impurity and the cumulative % RSD of the 
twelve samples (method precision+intermediate precision) were 
calculated and the compilation was tabulated in table 3. 
 
Table 3: Method precision and intermediate precision values of nilotinib impurities 
S. No. Sample ID % Imp-1 % Imp-2 % Imp-3 % Imp-4 
1 un spiked sample 0.02 0.02 0.03 0.01 
2 Method precision spiked sample-1 0.11 0.11 0.13 0.11 
3 spiked sample-2 0.11 0.11 0.13 0.11 
4 spiked sample-3 0.11 0.10 0.12 0.11 
5 spiked sample-4 0.11 0.11 0.13 0.12 
6 spiked sample-5 0.10 0.10 0.12 0.12 
7 spiked sample-6 0.11 0.10 0.13 0.11 
8 Intermediate precision spiked sample-7 0.11 0.11 0.12 0.11 
9 spiked sample-8 0.10 0.10 0.13 0.11 
10 spiked sample-9 0.11 0.10 0.13 0.11 
11 spiked sample-10 0.11 0.11 0.12 0.11 
12 spiked sample-11 0.11 0.10 0.12 0.11 
13 spiked sample-12 0.10 0.10 0.13 0.12 
Average 0.11 0.10 0.13 0.11 
SD 0.00 0.01 0.01 0.00 
% RSD 4.2 4.9 4.1 4.0 
 
LOD and LOQ 
The detection limit and quantification limit for all the four impurities 
were evaluated by linearity method. The diluted solutions of the 
impurity stock from the concentration of 0.01 % to 0.10 % with 5 
different levels in duplicate. A graph was plotted between 
concentration and area for all the impurities individually. STEYX, 
slope values, detection limit (LOD=3.3*STEYX/Slope) and 
quantification limit (LOQ=10*STEYX/Slope) for all the impurities 
were calculated and tabulated in table 4. Precision at LOQ level for 
all the impurities was verified by injecting the impurity mixture and 
the % RSD was found to be less than 10.0 and tabulated in table 5. 
 
Table 4: Detection limit (LOD) and quantification limit (LOQ) establishment 
S. No. Level Impurity-1 Impurity-2 Impurity-3 Impurity-4 
Conc (ppm) Area Conc (ppm) Area Conc (ppm) Area Conc (ppm) Area 
1 0.01 0.2 12450 0.2 17724 0.2 16243 0.2 11398 
2 0.03 0.6 36728 0.6 51931 0.6 48242 0.6 33852 
3 0.05 1.0 61628 1.0 87911 1.0 80565 1.0 55850 
4 0.08 1.6 99102 1.6 140374 1.6 128969 1.6 90842 
5 0.10 2.0 124002 2.0 175645 2.0 161293 2.0 113866 
Slope 62076.8 87890.4 80619.6 56977.1 
STEYX 260.0 423.6 111.3 514.7 
LOD (PPM) 0.014 0.016 0.005 0.030 
LOQ (PPM) 0.042 0.048 0.014 0.090 
 
Table 5: Precision at LOQ level 
S. No. Impurity-1 Impurity-2 Impurity-3 Impurity-4 
Conc (ppm) 0.042 0.048 0.014 0.09 
1 2468 4395 3249 2280 
2 2389 4320 3141 2276 
3 2415 4368 3226 2265 
4 2436 4356 3230 2259 
5 2460 4316 3256 2284 
6 2452 4309 3262 2276 
Average Area 2436.67 4344.00 3227.33 2273.33 
SD 30.01 34.37 44.62 9.46 
% RSD 1.23 0.79 1.38 0.42 
 
Accuracy 
The accuracy of the analytical method is the closeness of agreement 
between the true value and experimental value. The accuracy of the 
impurities was performed at levels ranging from LOQ to 150 % 
of the specification level of the impurity with respect to test 
concentration level. These accuracy samples were prepared by 
spiking the sample with impurity mixture at each level on the 
sample and % recovery was calculated. Accuracy was performed 
at 5 different levels in triplicate (6 preparations for the highest 
level and lowest level) and the % recovery was tabulated below 
in table 6. 
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1 LOQ# 0.04 96.8 0.05 96.9 0.01 97.1 0.09 97.0 
2 25 0.5 97.2 0.5 97.1 0.5 97.8 0.5 97.9 
3 50 1.0 98.0 1.0 97.8 1.0 98.3 1.0 98.1 
4 100 2.0 98.7 2.0 98.4 2.0 98.9 2.0 98.6 
5 150# 3.0 99.4 3.0 99.1 3.0 99.2 3.0 99.3 
#-Indicates six preparations; whereas other samples were prepared in triplicate 
 
Linearity and range 
The linearity of the detector response was established for all the 
known impurities with concentration ranging from LOQ to 150 
% of the specification level (0.10 %) with respect to test 
concentration. The samples were analyzed as per the test 
method. A linearity graph was plotted between the areas of 
impurity (Y-axis) versus concentration in ppm (X-axis) and 
determined the coefficient of correlation and Y-intercept at 100 
% response. The correlation coefficient, slope, residual sum of 
squares and Y-intercept for all the impurities were tabulated in 
table 7. 
 
Table 7: Linearity of impurities 
S. No. Impurity-1 Impurity-2 Impurity-3 Impurity-4 
Conc (ppm) Area Conc (ppm) Area Conc (ppm) Area Conc (ppm) Area 
1 0.04 2472 0.05 4395 0.04 3236 0.04 2262 
2 0.1 6101 0.1 8175 0.1 8025 0.1 5610 
3 0.5 30197 0.5 42192 0.5 39805 0.5 27993 
4 1.0 61628 1.0 87901 1.0 80092 1.0 83138 
5 2.0 124002 2.0 174923 2.0 156981 2.0 163783 
6 3.0 178720 3.0 259308 3.0 238675 3.0 246089 
Correlation coefficient 1.000 1.000 1.000 0.999 
Slope 60117 86826 79278 83681 
Y-Intercept 638 -83 42 -4489 
Residual sum of Squares 0.999 1.000 1.000 0.998 
 
Robustness 
The robustness of the method was evaluated to establish the capability 
of the method by changing the experimental conditions and its impact 
was studied on the system suitability parameters. Flow rate was 
varied from 1.0 ml/min to 0.8 ml/min and 1.2 ml/min, column 
temperature varied to 35 °C and 45 °C from 40 °C. The system 
suitability parameters were evaluated under these changed conditions 
and were compared with respect to the original conditions.  
The system suitability results for the varied conditions didn’t vary 
much from the actual conditions, indicates that the optimized 
chromatographic conditions for the HPLC method is robust. The 
results were compiled and tabulated in table 8. 
 
Table 8: Robustness results for the varied and actual conditions 
S. No. System suitability parameter Actual condition Flow (ml/min) Column temperature ( °C) 
0.8 1.2 35  45 
1 Rt (Min) 7.41 8.23 7.15 7.52 7.16 
2 Asymmetry 1.13 1.21 1.08 1.15 1.16 
3 Theoretical plates 7844 6592 8564 7354 7852 
4 % RSD of Area 0.18 0.23 0.21 0.25 0.22 
 
Table 9: Forced degradation study data 
Experiment Stress condition % Area % impurity % Assay % Mass balance* 
1 As such 99.85 0.15 99.46 99.61 
2 0.1 N HCl at 60 °C for 4 h 91.08 8.92 89.95 98.87 
3 0.1 N NaOH at 60 °C for 4 h 81.65 18.35 79.12 97.47 
4 3 % H2O2 at 25 °C for 1 hr 94.37 5.63 91.86 97.49 
5 105 °C for 48 h 99.12 0.88 98.19 99.07 
6 Photolytic stress 96.11 3.89 95.23 99.12 
*% Mass balance: Sum of % Assay and % impurity 
 
Forced degradation studies 
Decomposition ratio refers to the ratio between the assay value of 
the degradant in a stress condition and the unstressed drug with the 
same concentration is generally recommended to be within the 
range of 5–20 %. Appropriate decomposition ratios were measured 
in the acidic (8.92 %), alkaline (18.35 %), oxidative (5.63 %), 
thermal (0.88 %) and ultraviolet (3.89 %) conditions. nilotinib was 
stable to ultraviolet while sensitive to acid, alkali, heat and oxidant. 
The presence of the degradant did not interfere with the separation 
of nilotinib and the impurities. Peak purity analysis was performed 
with the DAD detector. Purity angles for nilotinib were within the 
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purity threshold limits in all degradation conditions, confirming that 
the nilotinib peak was homogeneous without co-elution substances. 
The detection wavelength of 250 nm was chosen as it was close to 
the maximum absorption of nilotinib hydrochloride and its related 
substances. The content of each impurity was evaluated by 
calculating the mass balance of the drug against the standard at the 
same concentration to that of the sample. Mass balance (% Assay of 
stressed sample+% of impurity during degradation) was calculated 
for all the stress samples and the amount of degradation in each 
condition were mentioned in table 9. Fig.5 shows forced degradation 







Fig. 5: Chromatograms of nilotinib hydrochloride in thermal stress, base stress, acid stress and peroxide stress samples respectively 
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Solution stability 
The standard and sample solutions were prepared as per the test 
procedure and solution stability was established at room 
temperature and at controlled temperature (2-8 °C). These solutions 
were injected serially at respective time intervals and the stability of 
these solutions was evaluated till 24 h. The comparison of these 
solutions was evaluated against the freshly prepared sample and 
standard solution. Nilotinib is prone to photolytic degradation hence 
solution stability was established for light protected sample as well as 
unprotected sample. The mobile phase solution stability was 
established by injecting the standard solution after 24 h and 48 h. The 
standard and sample solutions were stable for 24 h when protected 
from light at 2-8 °C and for 4 h when stored at room temperature. 
CONCLUSION 
A simple and rapid stability indicating RP-HPLC method was 
developed for the determination of nilotinib in the presence of its 
degradation products. In this method, nilotinib was exposed to 
various stress conditions as stated in ICH guidelines and the results 
of stress degradation studies show that nilotinib is labile to acid, 
base, peroxide, thermal and photolytic conditions. Validation of the 
HPLC method as per the ICH guidelines demonstrates that the 
method is specific, linear, precise, accurate, stability indicating and 
robust. The developed HPLC method is LC-MS compatible for the 
identification of mass of the degradants if any generated during the 
stability and process optimization. The method is also cost effective 
with respect to solvent consumption. Thus the proposed method can 
be used to determine the impurities in bulk drug and finished 
formulations in quality control laboratories. 
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